Delhi HC restrains Natco Pharma from launching generic of Roche's rare disease drug
"Roche has filed an appeal against the Hon. Delhi High Court order and the matter is subjudice in the appeal court," Roche ...
Delhi HC tells Natco Pharma to pause launch of generic version of Risdiplam
Roche had appealed against a single judge order of March 24 that had refused to stop Natco Pharma from manufacturing a generic version of Risdiplam ...
Medical Dialogues6d
Setback to Roche: Plea Against Natco on Risdiplam Patent Rejected by Delhi HC
In a major relief to Indian drugmaker Natco Pharma, the Delhi High Court has rejected an interim injunction plea filed by ...
Bar and Bench6d
Delhi High Court allows Natco to make Roche's spinal muscular atrophy drug in public interest
The Delhi High Court on Monday dismissed an interim injunction application filed by Swiss pharmaceutical giant F Hoffmann-La ...
HC allows Natco Pharma to make Swiss firm Roche’s spinal muscular atrophy drug in public interest
The bench said that public good outweighs the company’s profit as the drug is not available at an affordable price in India.
Delhi HC denies stay against Natco Pharma, potentially paving way for affordable generic drug
The high court decision potentially opens the door for access to a generic version of the patented drug - Risdiplam - at a fraction of the cost marketed by the Swiss pharmaceutical major.
Indian company can now make Spinal Muscular Atrophy drug, High Court cites public interest
The high court noted that SMA is a debilitating disease which has no cure, and the only approved drug, Risdiplam, marketed ...
Mint2d
Natco Pharma share price
The P/B ratio shows how a stock's market price compares to its book value. It helps gauge whether a stock is undervalued or overvalued relative to its net assets.
Delhi HC denies interim injunction on Roche rare disease drug, opening the door for generic versions
Patients with Spinal Muscular Atrophy (SMA) are hopeful of getting access to generic versions of Roche’s patented drug ...
Sensex down 260 pts; pharma shares slide for 4th day; VIX tumbles 5.16%
IST, the barometer index, the S&P BSE Sensex, slipped 259.73 points or 0.34% to 77,348.12. The Nifty 50 index declined 66.35 points, or 0.28%, to 23,525.60.